The Global Health Body Issues Warning Over Critical Lack of Weight-Loss Medications

Less than a tenth of people who could benefit from weight-loss injections including Wegovy can access them, states the World Health Organization as it publishes its first recommendations on the drugs.

Considering in excess of 1,000,000,000 individuals worldwide now living with obesity, it is urging increased and just access to GLP-1 medication.

Based on forecasts, more than two billion could be living with obesity by 2030 unless action is taken.

"The latest guidelines affirms that excess weight is a long-term condition that can be addressed with holistic and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are major barriers to broad availability to the treatments that can aid individuals in losing substantial body mass, notes the agency.

GLP-1 Therapy Scarcity

Even under the present best projected case, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of eligible patients, according to the WHO.

The recommendation encourages nations and manufacturers to increase access, via strategies including patent sharing.

The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is set to lapse in several nations in 2026.

How Weight-Loss Jabs Function

These medications imitate a biological compound to delay gastric emptying, reduce hunger and increase satiety so individuals reduce food intake.

Patients usually begin shedding pounds within a few weeks of commencing the weekly injections.

Evidence suggests patients may see weight return within a year of stopping the drug, because their typical hunger come back.

Being overweight or obese raises your chance for experiencing health problems, like diabetes, cardiovascular issues, stroke, and some malignancies.

Excess weight impacts individuals in all nations and was responsible for millions of deaths worldwide in 2024, per the health agency.